A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...
Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...
The company reported a 16% year-over-year increase in Life Sciences revenue, making up 55% of total revenue from continuing operations, with BioStorage - Bioservices revenue up 21%.
There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector ...
CDMOs must now offer platform-based manufacturing, simplified tech transfers, AI-driven automation, and robust analytical services. Speed is also critical—traditional 18–24-month timelines are no ...
TSHA-102 granted Breakthrough Therapy designation by FDAFinalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month ...
After axing a wide swath of federal research projects and grants, a recent slew of awards offers a glimpse into the kinds of science the second Trump administration wants to back: in vivo cell ...
The MarketWatch News Department was not involved in the creation of this content.-- Third quarter revenue increased 15% year-over-year to $44.2 million -- Commercial Cell & Gene T ...
Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...
A new research project at the Cyprus Institute of Neurology and Genetics (CING) aims to develop a one-time, curative therapy for beta-thalassemia, the most common inherited blood disorder in Cyprus.
The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial ...
Founded in 2016 by Jérémie Laurent at the Saint-Louis Hospital in Paris, a prestigious hub for leading cell therapy research, Astraveus is committed to revolutionizing the development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback